Humana jumps as it reaffirms FY2026 EPS outlook ahead of investor meetings, with recent bullish analyst upgrades adding support

Humana Inc. (HUM) is up 8.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most direct catalyst appears to be Humana’s Form 8-K filed June 1, 2026, which reaffirmed its FY2026 EPS guidance ahead of scheduled investor and analyst meetings. The move also likely reflects incremental optimism from recent high-profile analyst upgrades and higher price targets, which can amplify a rally when sentiment is improving.

Details:

Humana disclosed that senior management is scheduled to meet with investors and analysts between June 1, 2026 and June 30, 2026, and it intends to reaffirm previously issued FY2026 earnings guidance during those discussions.

In the same filing, the company reiterated FY2026 diluted GAAP EPS guidance of at least $8.36 and adjusted EPS guidance of at least $9.00, consistent with guidance previously communicated alongside its April 29, 2026 update.

Recent analyst actions have turned more constructive, including a notable upgrade by Deutsche Bank to Buy with a substantially higher price target, framing 2026 as an earnings trough and highlighting potential benefits from improved Medicare Star Ratings over time.

With the guidance reaffirmed rather than cut, today’s price action could also reflect short-covering and a “less-bad-than-feared” reset after earlier volatility around 2026 earnings expectations.

Sources:

SEC (Humana Form 8-K filed June 1, 2026), StreetInsider, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HUM Insider Trading Activity

$HUM insiders have traded $HUM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $HUM stock by insiders over the last 6 months:

SANJAY K SHETTY (President, CenterWell) purchased 810 shares for an estimated $150,016

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$HUM Hedge Fund Activity

We have seen 334 institutional investors add shares of $HUM stock to their portfolio, and 604 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS removed 3,831,860 shares (-65.9%) from their portfolio in Q1 2026, for an estimated $664,406,205
BANK OF NEW YORK MELLON CORP removed 1,479,679 shares (-70.6%) from their portfolio in Q1 2026, for an estimated $256,561,541
SESSA CAPITAL IM, L.P. added 1,408,833 shares (+60.8%) to their portfolio in Q1 2026, for an estimated $244,277,553
PZENA INVESTMENT MANAGEMENT LLC added 1,398,774 shares (+34.3%) to their portfolio in Q1 2026, for an estimated $242,533,423
CAPITAL RESEARCH GLOBAL INVESTORS added 1,099,839 shares (+inf%) to their portfolio in Q1 2026, for an estimated $190,701,084
FRANKLIN RESOURCES INC removed 981,758 shares (-78.2%) from their portfolio in Q1 2026, for an estimated $170,227,019
GOLDMAN SACHS GROUP INC added 926,632 shares (+94.6%) to their portfolio in Q1 2026, for an estimated $160,668,722

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HUM Congressional Stock Trading

Members of Congress have traded $HUM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $HUM stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$HUM Analyst Ratings

Wall Street analysts have issued reports on $HUM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 04/30/2026
Jefferies issued a "Buy" rating on 12/05/2025

To track analyst ratings and price targets for $HUM, check out Quiver Quantitative's $HUM forecast page.

$HUM Price Targets

Multiple analysts have issued price targets for $HUM recently. We have seen 16 analysts offer price targets for $HUM in the last 6 months, with a median target of $248.0.

Here are some recent targets:

Andrew Mok from Barclays set a target price of $344.0 on 05/26/2026
A.J. Rice from UBS set a target price of $320.0 on 05/22/2026
Ann Hynes from Mizuho set a target price of $335.0 on 05/20/2026
George Hill from Deutsche Bank set a target price of $441.0 on 05/20/2026
Erin Wright from Morgan Stanley set a target price of $217.0 on 05/15/2026
Jessica Tassan from Piper Sandler set a target price of $254.0 on 05/13/2026
Lisa Gill from JP Morgan set a target price of $214.0 on 05/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.